Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
2002 (English)In: British Journal of Cancer, ISSN 0007-0920, Vol. 86, no 4, 540-545 p.Article in journal (Refereed) Published
Akt/PKB is a serine/threonine protein kinase that regulates cell cycle progression, apoptosis and growth factor mediated cell survival in association with tyrosine kinase receptors. The protein is a downstream effector of erbB-2 with implications in breast cancer progression and drug resistance in vitro. We aimed to examine the role of Akt-1 in breast cancer patients, by determining whether the expression (Akt-1) and/or activation (pAkt) were related to prognostic markers and survival. The expression of erbB-2, heregulin β1 and Bcl-2 was also assessed by flow cytometry or immunohistochemistry. This study comprised 93 patients, aged < 50 who were treated with tamoxifen and/or goserelin. We found that pAkt was associated with lower S-phase fraction (P = 0.001) and the presence of heregulin β1-expressing stromal cells (P = 0.017). Neither Akt-1 nor pAkt was related with other factors Turnout cells-derived heregulin β1 was found mainly in oestrogen receptor negative (P = 0.026) and node negative (P = 0.005) cases. Survival analysis revealed that pAkt positive patients were more prone to relapse with distant metastasis, independently of S-phase fraction and nodal status (multivariate analysis; P = 0.004). The results suggest that activation of Akt may have prognostic relevance in breast cancer
Place, publisher, year, edition, pages
2002. Vol. 86, no 4, 540-545 p.
Breast cancer, endocrine treatment, Akt, PKB, erbB-2, hergulin ß1
Cancer and Oncology
IdentifiersURN: urn:nbn:se:liu:diva-15031DOI: 10.1038/sj.bjc.6600126OAI: oai:DiVA.org:liu-15031DiVA: diva2:37682